Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chloral→

Chloral Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75-87-6
Molecular formula
C2HCl3O
Molecular weight
147.39 g/mol
Drug class
Chloral hydrate sedative-hypnoticcentral nervous system depressant
Mechanism of action
Metabolised to trichloroethanol, which enhances GABAA-mediated inhibitory neurotransmission and produces sedation and hypnosis. It also has a narrow therapeutic margin and significant respiratory, cardiac and gastrointestinal toxicity.
Indications / reported uses
  • Historically used for short-term sedation and insomnia and for procedural sedation in selected paediatric settings; use is now restricted or discouraged in many jurisdictions because of safety concerns and availability of safer alternatives

Sources: NLM MeSH — Chloral hydrate · PubMed — Chloral hydrate sedation safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chloral Environmental Risk Assessment (ERA) (the Chloral ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.